Author:
Takasaki Shinya,Kawasaki Yoshihide,Kikuchi Masafumi,Tanaka Masaki,Suzuka Masato,Noda Aoi,Sato Yuji,Yamashita Shinichi,Mitsuzuka Koji,Saito Hideo,Ito Akihiro,Yamaguchi Hiroaki,Arai Yoichi,Mano Nariyasu
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Hematology,General Medicine,Surgery
Reference24 articles.
1. Yoshimura K, Uemura H (2016) Pharmacotherapies for renal cell carcinoma in Japan. Int J Urol 23:194–202
2. Mendel DB, Laird AD, Xin X et al (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327–337
3. Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115–124
4. Faivre S, Delbaldo C, Vera K et al (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24:25–35
5. Gao B, Yeap S, Clements A et al (2012) Evidence for therapeutic drug monitoring of targeted anticancer therapies. J Clin Oncol 30:4017–4025
Cited by
27 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献